• The new study compound is being developed to treat long-term inflammation. This happens when the immune system stays active for a long time. Short-term activity helps fight diseases, but if it lasts too long, it can become harmful. Long-term inflammation is seen in the brain in Alzheimer's disease, Parkinson’s disease and in obesity (severe overweight), as well as in other conditions. Alzheimer's disease is a brain disorder that slowly causes memory loss, confusion, and changes in behavior. Parkinson's disease is a nervous system disorder that causes shaking, stiffness, and difficulty with movement.
• In this clinical trial, we will investigate how the study compound is processed and eliminated by the body and how well it is tolerated when administered to healthy participants. We will also investigate the effect of the compound on the immune system. The effects of the study compound will be compared to the effects of a placebo (drug with no active ingredient).
• The study compound or placebo will be administered as a capsule (by mouth).
• The trial consists of 2 parts: part A and part B. Each part has several groups.
• In part B, you will receive the study compound or placebo once daily for 14 days.
• During the study, your heart may be monitored once or twice. If you take part in the last two groups of part A, your heart will be continuously monitored once for 25.5 hours during the study. In all groups of part B, this will happen twice (once for 1,5 hours and once for 25.5 hours). You will have sticky patches (electrodes) attached to your chest that are connected to a device. At various times, you will have to lie still for 15 minutes without moving, talking or sleeping. You also cannot listen to music, watch TV or use a laptop or phone. However, apart from these times, you may do so.
• For all groups: 2 additional visits may take place at the research center for drawing blood. Based on the results of the earlier groups, it may be decided that these short visits will not take place.
• For only 2 groups in Part B, namely group B2 and B3: cerebrospinal fluid will be collected from you through a lumbar puncture. A cerebrospinal fluid sample will be taken before you receive the study compound or placebo, and again after 13 days. This is done by inserting a thin needle between two vertebrae in the lower back. This procedure is not entirely without risk. Collecting this fluid is important because it helps show how much of the study compound reaches the brain and what effects it may have there. The lumbar puncture will be performed by an experienced specialist. The specialist will use numbing medication to reduce any pain or discomfort from the needle.

All (possible) medicines can cause side effects. Because the compound has not yet been administered to humans, there are currently no known side effects in humans. In rare cases (<0.1%), serious side effects can occur during the first administration to humans. The compound has already been extensively tested in the laboratory and on animals. Prior to the medical screening, you will receive written information about the trial, which also describes the possible side effects based on these animal tests. This information will also be discussed with you at the start of the medical screening. You will then have the opportunity to ask the screening physician or nurse any questions. The medical screening will only take place after you have given written consent to participate in the trial. We want to emphasize that even after giving written consent, participation in any clinical trial is voluntary. You can decide at any time not to participate or to stop the medical screening or the trial. You do not need to provide a reason for why you no longer wish to participate.

• You are a healthy male or female.
• You are at least 18 and at most 65 years old.
• Your Body Mass Index (BMI) is at least 18.0 and at most 29.9 kg/m². 
• You do not smoke and do not use any nicotine-containing products.
• As a female you can only participate if you are not pregnant, not breast feeding and meet one of the following conditions:
  • You are using hormonal contraception (for example the contraceptive pill or intra-uterine device containing hormones) in combination with a condom;
  • You are using a copper intra-uterine device in combination with a condom;
  • You have passed the menopause (no periods for at least 12 months);
  • You have been sterilized or your male partner has been sterilized;
  • You are only sexually active with a partner of the same sex;
  • You are not sexually active according to your lifestyle.
• As a male you can only participate if you meet one of the following conditions:
  • You are using a condom in combination with an additional contraception method used by your female partner, and you are prepared to continue this dual contraception for up to 3 months after the last dose of the study compound;
  • You have been sterilized or your female partner is sterilized or has passed the menopause (no periods for at least 12 months);
  • You are only sexually active with a partner of the same sex;
  • You are not sexually active according to your lifestyle.

Note:

• You cannot participate in the trial if you have participated in another clinical trial in the 3 months prior to the first compound administration in this clinical trial (counting from the follow-up visit).
• To determine if you are suitable to participate in this trial, you will undergo a medical screening. Depending on availability, this can be performed in Groningen or in Utrecht.

For group B1: the trial consists of 1 period during which you will stay in the research facility in Groningen (location van Swietenlaan 6). You will stay there for 18 days (17 nights). After your stay in the research facility, two short visits will follow. Based on the results of previous groups, it may be decided that these short visits will not take place. 21 to 24 days after your departure from the research facility, you will be contacted by phone for some follow-up questions.

For group B2 and B3: the trial consists of 1 period during which you will stay in the research facility in Groningen (location van Swietenlaan 6). You will stay for 19 days (18 nights). After your stay in the research facility, two short visits will follow. Based on the results of previous groups, it may be decided that these short visits will not take place. 21-24 days after your departure from the research facility, you will be contacted by phone for some follow-up questions.

Note: You must be available for all dates to be able to participate in this clinical trial. You may choose which group you want to participate in, based on your  availability.